The Ph chromosome results from a reciprocal translocation, t(9;22) (q34;ql l), that relocates the c-ab1 protooncogene on chromosome 9 to the breakpoint cluster region (bcr) of chromosome 22.'.2 CML is characterized by two clinical phases: an initial chronic phase followed by a fatal blast crisis phase. Interferon and allogeneic bone marrow transplantation are currently the major therapeutic approaches for CML and result in long-term remissions in 30% to 35% of The translocation of ab1 onto bcr gives rise to a novel bcr-ab1 hybrid gene that encodes the p210b""ab' fusion protein. p210b"r-"bl is of either L6 (bcr exon I1 and c-ab1 exon "2" linkage) or K28 linkage (bcr exon 111 and c-ab1 exon "2" linkage).2 p210b""ab1, which has enhanced tyrosine kinase activity: is believed to be involved in the pathogenesis of CML by promoting selectively the expansion of mature myeloid progenitor cell^.^.^ Phosphodiester antisense oligodeoxynucleotides complementary to specific sequences, such as the L6 or K28 breakpoint junctions, of the bcr-abl mRNA were found to inhibit the expression of the p210bc"ab1 fusion
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In addition, the antisense oligodeoxynucleotides could inhibit the cell proliferation of CML-like cell lines as well as the cell proliferation of blast crisis patients with CML.'.' Because these phosphodiester antisense oligodeoxynucleotides are unstable against nuclease digestion, large concentrations (>40 pg/mL or 14 pmoVL) and sequential additions of antisense oligodeoxynucleotides are required.'. ' Nucleic acid methylphosphonate (MP), a phosphodiester analog, is resistant to nuclease hydrolysis'"' and has been used as an antisense m~l e c u l e . '~"~ It is insoluble in aqueous solutions and can only be dissolved in organic solvents such as dimethyl sulfoxide (DMSO) and acetonitrileM,O. To circumvent the limitations associated with the use of oligodeoxynucleotides, we studied the incorporation of MP oligodeoxynucleotides into liposomes.
Liposomes are nontoxic, biodegradable lipid vesicles that contain concentric aqueous compartments separated by lipid These vesicles entrap both aqueous and lipophilic compounds. Liposomes have been used to deliver lipophilic compounds such as dox~rubicin,'~ cisplatin,2° amphotericin €3: ' and muramyl peptides." Incorporation of these lipophilic compounds into liposomes can circumvent the use of organic solvents. By altering the pharmacokinetics and biodistribution of these compounds, liposomes reduce the compounds' toxic side effects while maintaining their efficacies. In the present study, the growth inhibitory effects of liposomal MP (L-MP) on CML-like cell lines were examined.
MATERIALS AND METHODS
MP oligodeoxynucleotides were provided by Genta, Inc (San Diego, CA). MP oligodeoxynucleotides no. 1, 2, and 4 (see below) were synthesized with a phosphodiester nucleotide at the 5' end. The length of the MP oligodeoxynucleotides ranges between 15 and 18 bases. Phospholipids were purchased from Avanti Polar Lipids (Birmingham, AL). Radioisotopes were obtained from Amersham (Arlington Heights, IL).
Labeling of MP Oligonucleotides With Radioisotope
MP oligonucleotides were S' end-labeled with [y-"P]ATP using Escherichia coli T4 polynucleotide kinase (GIBCO) in 70 mmol/L Tris-HCI, pH 7.6, 0.1 mol/L KCl, 10 mmol/L MgClz, S mmol/L dithiolthreitol (DTT), 0.5 mg/mL bovine serum albumin (BSA), and 25% DMSO for 8 hours at 37°C. The oligonucleotides were precipitated with ethanol at -20°C overnight. After washing with 70% ethanol three times, the oligonucleotides were twice filtered with a Microcon-3 filter (Amicon, Beverly, MA) to separate the labeled oligonucleotide from free [y-"PIATP. For a typical reaction, MP was labeled with 10' to IO' cpmlpg. The ["P]-labeled MP was resuspended in DMSO. 
Preparation of Inulin-Containing Liposomes

Uptake of Liposomes by Leukemic Cells
Fifty thousand cells per well were seeded in a 24-well plate in 0.3 mL of RPM1 1640 medium containing 10% fetal bovine serum. After 2 hours of seeding, final concentrations of 30 to S00 pmolL of ['HI-labeled liposomes entrapping [ 14C]-labeled inulin were added to leukemia cells. After 24 hours of incubation at 3 7 T , the cells were resuspended in phosphate-buffered saline and layered over a 10% wt/vol Ficoll solution. The cells were centrifuged at 1,600 rpm for 30 minutes and collected at the interface between the phosphatebuffered saline and the Ficoll solution. The collected cells were then lysed with 0.1 N NaOH and sent to liquid scintillation counting.
Delivery L-MP to Leukemic Cells
Ten thousand cells per well were seeded in a 96-well plate in 0.2 mL of RPM1 1640 medium containing 10% fetal bovine serum. After 2 hours of seeding, final concentrations of 0.25 to 2.50 pmol/ L of L-MP oligonucleotides were added to cells. Typically, the leukemic cells were incubated with L-MP oligonucleotides for S days. Each experiment was performed at least three times.
Viability of Leukemic Cells
The viability of leukemic cells was measured by the alamarBlue dye (Alamar, Sacramento, CA). After 5 days of L-MP oligonucleotide incubation, 2.5 pL of cellslwell was aliquoted and added to 155 pL of medium. Twenty microliters of alamarBlue dye was added to each well. After incubation for 4 hours at 37°C the plates were read directly on a microplate reader (Molecular Devices, Menlo Park, CA) at S70 and 595 nm. The difference in absorbance between S70 and S95 nm was taken as the overall absorbance value of the leukemic cells. All the experiments were analyzed by t-tests in which the viabilities of the L-MP-treated cells were compared with those of the untreated controls.
Western Blots for p210h'r-Uh' Protein
Fifty thousand K562 cells or 1 X IO5 BV173 cells were treated with protease inhibitors and then lysed in sodium dodecyl sulfate (SDS) sample buffer containing 1% SDS and 1% 2-mercaptoethanol and boiled for S minutes. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was run on 7.5% polyacrylamide gels, electrophoretically transferred to nitrocellulose membranes, blocked in 5% nonfat dry milk, and treated for 1 hour with 8E9 monoclonal antibody (Pharmingen, San Diego, CA), which is specific for the tyrosine kinase domain of the ab1 protein. This antibody reacts with both the normal p14Sabi protein and the p210b"~ah' product. Detection was performed by enhanced chemiluminescence (ECL; Amersham) after reaction with horseradish peroxidase conjugated to rat antimouse secondary antibody. Densitometric scans were run on a Giford Response Gel Scanner (CIBA Corning, Medfield, MA). Area integration of absorbance peaks at S00 nm was used to determine the ratio of p210:p14s.
RESULTS
Uptake of Liposomes by Leukemic Cells
Liposomes labeled with hexadecyl ['H]cholestanyl ether entrapping ['4C]-labeled inulin were prepared. The former and the latter serve as lipid and aqueous markers, respectively. Liposomes were added to K562, BV173, and HL60 leukemia cells. The uptake of lipids (Fig IA) and inulin (Fig  1 B) by leukemic cells increased as their input concentrations were increased. The uptakes of lipids and inulin were approximately 9% and 8% of their input, respectively. The uptake of lipids and inulin increased in a similar proportional manner, suggesting that the liposomes were taken up as intact liposomes by the leukemic cells.
Inhibition of CML Cell Growth by L-MP Antisense Oligonucleotides Antisense oligonucleotides complementary to the L6 junction of the bcr-ab1 mRNA (oligonucleotide no. 1). L-MP
The viability of K562 cells decreased as the concentration of L-MP antisense oligonucleotide no. 2 was increased (Fig 2B) . When 0.25 to 2.50 p m o w of L-MP was used, the viability of K562 cells decreased to 30% to 80% that of untreated K562 cells. Thus, approximately 20% to 70% growth inhibition of K562 cells was observed. Under identical conditions, the viabilities of BV173 and HL60 cells were greater than 80% of the untreated cells, which were insignificant from that of the untreated cells (P = .053 and .W, respectively).
Control oligonucleotides that are not complementary to the bcr-ab1 mRNA. To ensure that the growth inhibition of BV173 cells by L-MP oligonucleotide no. l was sequencedependent, we also used L-MP oligonucleotides no. 2 ( Fig  2B) and 3 (Fig 3A) as control L-MP oligonucleotides. When L-MP antisense oligonucleotide no. 1 was added to BV173 cells, a dose-dependent growth inhibition was observed. However, under identical conditions, growth inhibition was not observed with control L-MP oligonucleotide no. 3. K562 cells were treated with control L-MP oligonucleotides no. l (Fig 2A) and 4 (Fig 3B) . Growth-inhibitory effects were observed with K562 cells in a dose-dependent manner on incubation with L-MP antisense oligonucleotide no. 2. When treated with L-MP oligonucleotide no. 4, the viability of K562 cells was greater than 80%, which was insignificant antisense oligonucleotide no. l (see Materials and Methods), complementary to the L6 junction of the bcr-abl mRNA, was delivered to BV173 (which bears the L6 breakpoint junction), K562, and HL60 cells (negative controls). Five days after the addition of L-MP, the viability of the leukemic cells was measured. A dose-response effect was observed in BV173 cells (Fig 2A) . When 0.25 to 2.50 pmoVL of L-MP was used, the viability of BV173 cells decreased to 30% to 75% of that of untreated cells. This corresponded respectively to approximately 25% to 70% growth inhibition. At the highest concentration of L-MP used, the viabilities of L-MP-treated K562 and HL60 cells were greater than 80% of the untreated cells, which was insignificant from that of the untreated cells (P = .26 and .56, respectively).
Antisense oligonucleotides complementary to the K28 junction of the bcr-ab1 mRNA (oligonucleotide no. 2). L-MP antisense oligonucleotide no. 2, complementary to the K28 junction of the bcr-ab1 mRNA, was used to treat BV173, K562 (which bears the K28 breakpoint junction), and HL60 from that of the untreated cells ( P = S4). Nonspecific toxicity could be observed with control L-MP oligonucleotides at -3.0 to 3.5 pmoVL (data not shown).
Selective Inhibition of ~2 1 0 h " "~' by L-MP Antisense Oligonucleotides
Inhibition of p210h"~"" in BVI 73 cells. The expression of p210k""" protein in BV173 cells after treatment with 1.0 pmol/L L-MP oligonucleotides no. 1 and 2 was studied. L-MP oligonucleotides no. 1 and 2 (which differ in 10 bases) were used as the antisense and control oligonucleotides, respectively. Untreated BV173 cells were also maintained in culture. Samples were removed at day 3 after the addition of the L-MP oligonucleotides. Growth of BV173 cells was monitored by obtaining cell counts throughout the duration of the study. On day 3, the numbers of BV173 cells treated by L-MP oligonucleotides no. 1 and 2 were inhibited by 59.4% and 1.8%, respectively ( Table 1) . Western blots were performed to observe selective inhibition of p210k"ab' production (Fig 4) . To estimate the inhibition of p210k"ab' protein expression, densitometric scans were performed on Western blots. The ratio of p210:p145 was 1.04 to 1.16 for the control BV173 cells and 0.27 for the BV173 cells treated with L-MP antisense oligonucleotide no. 1. Inhibition of p210b"-ab' in K562 cells. K562 cells were TAR1 ET AL treated with 1.0 to 2.0 p m o K of L-MP oligonucleotides no. 1 and 2, which were used as control and antisense oligonucleotides, respectively. Untreated K562 cells were also maintained in culture. Samples were removed at day 4 after the addition of the L-MP oligonucleotides. Growth of K562 cells was monitored by obtaining celI counts throughout the duration of the study. On day 4, the number of K562 cells treated with L-MP oligonucleotide no. 2 were inhibited by 24.7% to 52.6%, whereas the number of K562 cells treated with L-MP oligonucleotide no. 1 was inhibited by 10.4% (Table 1 ) .
Western blots were performed to observe selective inhibition
Western blot for the control K562 cells indicated that the ratio of p210:p145 was 1.69 to 2.03 versus 0.18 to 0.77 for the L-MP antisense oligonucleotide no. 2-treated K562 cells.
of p2 1 0 k c -a b l production (Fig 5) . Densitometric scans of the
Effect of the Duration of L-MP Incubation on Inhibition Recovery of CML Cells
Growth inhibition of BVI 73 cells. L-MP oligonucleotides no. 1 and 2, at 2.5 pmoVL concentration, were delivered to BV173 cells (Fig 6A) . After 5 days of exposure, the cells were washed and reseeded in medium free of L-MP. Before washing, -80% growth inhibition was observed with BV173 cells treated with L-MP antisense oligonucleotide no. 1. This level of inhibition lasted for 4 extra days. By 5 days, the cells had recovered and the growth inhibition was less than 20%. Throughout the study, there was less than 20% inhibition of BV173 cells when incubated with L-MP oligonucleotide no. 2.
Growth inhibition of K562 cells. L-MP oligonucleotides no. 1 and 2, at 2.5 pmol/L concentration, were delivered to K562 cells (Fig 6B) . After 5 days of exposure, the cells were washed and reseeded in medium free of L-MP. Before washing, -90% growth inhibition was observed with K562 cells treated with L-MP antisense oligonucleotide no. 2. This level of inhibition lasted for 4 extra days. By 5 days, the cells had recovered and the growth inhibition was less than 20%. Throughout the study, there was less than 20% inhibition of K562 cells when incubated with L-MP oligonucleotide no. 1.
DISCUSSION
Our results indicate that L-MP oligonucleotides selectively inhibit the expression of p210k"ab' with a concomitant decrease in cell growth. The effect on growth inhibition was specific, because only CML cells expressing the p210bc""h' protein were inhibited and not HL60 cells, which are myelomonocytic and do not express the p210bc""h' protein. Moreover, when L-MP oligonucleotides targeted to the L6 junction of the bcr-abl mEtNA was added to BV173 cells, which express the L6 junction, cell growth was inhibited, but not on K562 cells, which do not express the L6 junction. The converse is true when L-MP oligonucleotides targeted to the K28 junction of the bcr-ab1 mRNA were added to both BV173 and K562 cells; only the growth of K562, but not BV173 cells, was inhibited, therefore indicating that the effect was specific to each abnormality. No significant growth inhibition was observed in BV173 and K562 cells exposed to control L-MP oligonucleotides. At concentrations of and less than 2.5 pnol/L, L-MP antisense oligonucleotides induced sequence-specific growth inhibitory effects on the CML cell lines. The growth inhibition of CML cells was not immediately reversed when L-MP oligonucleotides were removed. When CML-like cell lines were incubated with L-MP for 5 days and washed and the culture was regrown in medium free of L-MP, the inhibitory effect lasted for another 4 days, indicating that a single dose of L-MP could induce a cytotoxic effect in the CML-like cell lines that lasted for approximately 9 days. It is possible that the incomplete suppression of the growth of the CML cell lines by the L-MP antisense oligonucleotides is caused by the many somatic mutations that may have been acquired in these cell lines, which may make the cells relatively independent of the p210"r-"h' protein. Furthermore, many of the CML cell lines so far tested express the p 1 60"' protein, product of the unrearranged bcr allele, which has been shown to form a complex with the p2lOkrTnh' protein. 23 This complex has been suggested to play a significant role in maintaining the leukemic state of CML cells,24 which suggests the unproven hypothesis that suppression of the expression of the p160"' and p210""ah' proteins may be important for the suppression of CML cell growth. It is possible that, because the L-MP oligonucleotides used 1 2 3 4 5 For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From
